Authors: Seung In Seo, Chan Hyuk Park, Seng Chan You, Jae Young Kim, Kyung Joo Lee, Jinseob Kim, Yerim Kim, Jong Jin Yoo, Won-Woo Seo, Hyung Seok Lee, Woon Geon Shin
Published: 2021-05-11
DOI: 10.1136/gutjnl-2020-323845
Source: Full article
ObjectiveThe association between proton pump inhibitor (PPI) use and gastric cancer related toHelicobacter pylorieradication has not been fully investigated in geographical regions with high risk of gastric cancer. We aimed to evaluate the association between PPIs and gastric cancer in Korea.DesignThis study analysed the original and common data model versions of the Korean National Health Insurance Service database from 2002 to 2013. We compared the incidence rates of gastric cancer after 1-year drug exposure, between new users of PPIs and other drugs excluding PPIs, by Cox proportional hazards model. We also analysed the incidence of gastric cancer among PPI users afterH. pylorieradication.ResultsThe analysis included 11 741 patients in matched PPI and non-PPI cohorts after large-scale propensity score matching. During a median follow-up of 4.3 years, PPI use was associated with a 2.37-fold increased incidence of gastric cancer (PPI≥30 days vs non-PPI; 118/51 813 person-years vs 40/49 729 person-years; HR 2.37, 95% CI 1.56 to 3.68, p=0.001). The incidence rates of gastric cancer showed an increasing trend parallel to the duration of PPI use. InH. pylori-eradicated subjects, the incidence of gastric cancer was significantly associated with PPI use over 180 days compared with the non-PPI group (PPI≥180 days vs non-PPI; 30/12 470 person-years vs 9/7814 person-years; HR 2.22, 95% CI 1.05 to 4.67, p=0.036).ConclusionPPI use was associated with gastric cancer, regardless ofH. pylorieradication status. Long-term PPIs should be used with caution in high-risk regions for gastric cancer.